Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 in Fragile X Syndrome (RECONNECT)
NCT04977986Phase 3Completed
- Sponsor
- Harmony Biosciences
- Start
- Sep 2021
- Primary completion
- Aug 2025
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in Fragile X syndrome (FXS) comparing ZYN002 with Placebo (2 arms). Primary endpoint: Aberrant Behavior Checklist-Community Fragile X Factor Structure Pre-specified Subscale 1 score at 18 weeks. Started Sep 2021; status: completed.
02
Drugs
Zygel
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT04977986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977986.